Asia Pacific Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)

TIPRE00025367 | Pages: 109 | Pharmaceuticals | Oct 2021 | Type: Regional | Status: Published

 

Market Introduction

Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.

 


Get more information on this report :



Market Overview and Dynamics

The Asia Pacific diltiazem market is expected to reach US$ 160.34 million by 2028 from US$ 67.84 million in 2021; it is estimated to grow at a CAGR of 13.1% from 2021 to 2028. Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases (CVDs), and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.

The prevalence of cardiovascular conditions is rising across the world, especially in developing nations. In these nations, the modernized facilities reduced the physical activities of people. Also, the stress level among people is growing. The incidence of CVDs is rising in developing countries, owing to the shift in lifestyle and the other health conditions caused due to the adoption of modernized facilities, which is propelling the demand for Diltiazem. The developing nations are significantly developing their healthcare facilities and services and are heading toward technological advancements. For instance, the structural heart is at the initial stage of development in the regions such as Asia Pacific. In March 2021, Glenmark Pharma gained the final USFDA nod on diltiazem hydrochloride capsules. Glenmark Pharmaceuticals has been granted a competitive generic therapy (CGT) designation for Diltiazem Hydrochloride Extended?Release Capsules USP, 60 mg, 90 mg, and 120 mg. With the approval, the company has become the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing. Also, Glenmark is expanding its footprint in Switzerland and other developing countries. Thus, the opportunities for the market players to enter the market with cost-effective products are higher. Therefore, the factors mentioned above would create lucrative opportunities for the growth of the diltiazem market during the forecast period. Also, the diltiazem market is characterized by various small and big companies across Asia Pacific. The market players adopt strategies such as new product launches, regional expansions, and product approvals to increase their market share. The players are investing in R&D to develop advanced technologies and gain significant revenue share. Thus, recent developments are expected to act as a future trend in the diltiazem market.

COVID-19 pandemic has broadly affected economies in the Asia Pacific region. The pandemic has affected three main aspects of the global economy – production, supply chain, and firms and financial markets. The supply chain disruptions and the massive demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. Recently, patients with both hypertension and obesity have been increasing in Japan at exceptionally high risk of COVID-19, and thus, they need careful observation and intensive treatment. However, it is essential to note that the therapeutic mechanism of calcium channel blockers against COVID-19 still awaits further investigation and randomized controlled clinical trials. This scenario is positively impacting the diltiazem market in Asia Pacific.

 

Key Market Segments

Based on product, the Asia Pacific diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR from 2021 to 2028.

Based on application, the Asia Pacific diltiazem market was segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market. The angina segment is expected to grow at the fastest CAGR in the coming years.

 

Major Sources and Companies Listed

A few of the primary and secondary sources associated with this report on the Asia Pacific diltiazem market are the National Center for Biotechnology Information (NCBI), The China National Committee on Aging (CNCA), and All-India Institute of Medical Sciences (AIIMS), among others.

Reasons to buy the report

  • Determine prospective investment areas based on a detailed trend analysis of Asia Pacific diltiazem market over the next years.
  • Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
  • Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
  • Identify the major channels driving the Asia Pacific diltiazem market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
  • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific diltiazem market.

 

ASIA PACIFIC DILTIAZEM MARKET SEGMENTATION

By Product Type

  • Tablet
  • Capsules
  • Injection

By Application

  • Hypertension
  • Angina
  • Others

By Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Company Profiles

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Asia Pacific Diltiazem Market – By Product Type

1.3.2        Asia Pacific Diltiazem Market – By Application

1.3.3        Asia Pacific Diltiazem Market – By Country

2.           Diltiazem Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Diltiazem Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Asia Pacific – PEST Analysis

4.3         Experts Opinion

5.           Diltiazem Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increase in Cardiovascular Disease Incidence

5.1.2        Increasing Elderly Population

5.2         Market Restraints

5.2.1        Side Effects of Diltiazem

5.3         Market Opportunities

5.3.1        Growth Opportunities in Developing Nations

5.4         Future Trends

5.4.1        Recent Developments in Market

5.5         Impact Analysis

6.           Diltiazem Market –Asia Pacific Analysis

6.1         Asia Pacific Diltiazem Market Revenue Forecast and Analysis

7.           Diltiazem Market Analysis and Forecasts to 2028 – Product Type

7.1         Overview

7.2         Diltiazem Market Share by Product Type 2021 & 2028 (%)

7.3         Capsules

7.3.1        Overview

7.3.2        Capsules Market Revenue and Forecast to 2028 (US$ Mn)

7.4         Injection

7.4.1        Overview

7.4.2        Injection Market Revenue and Forecast to 2028 (US$ Mn)

7.5         Tablets

7.5.1        Overview

7.5.2        Tablet Market Revenue and Forecast to 2028 (US$ Mn)

8.           Diltiazem Market Analysis And Forecasts TO 2028 – Application

8.1         Overview

8.2         Diltiazem Market Share by Application 2021 & 2028 (%)

8.3         Angina

8.3.1        Overview

8.3.2        Angina Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Hypertension

8.4.1        Overview

8.4.2        Hypertension Market Revenue and Forecast to 2028 (US$ Mn)

8.5         Others

8.5.1        Overview

8.5.2        Others Market Revenue and Forecast to 2028 (US$ Mn)

9.           Diltiazem Market - Asia Pacific Analysis

9.1         Asia Pacific: Diltiazem Market

9.1.1        Overview

9.1.2        Asia Pacific: Diltiazem Market, by Country, 2021 & 2028 (%)

9.1.2.1          China: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.1          China: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.2          China: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.1.3          China: Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.2          Japan: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.1          Japan: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.2          Japan: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.2.3          Japan: Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.3          India: Diltiazem Market - Revenue and Forecasts to 2028 (USD Million)

9.1.2.3.1          India: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.2          India: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.3.3          India: Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.4          South Korea: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.1          South Korea: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.2          South Korea: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.4.3          South Korea: Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

9.1.2.5          Australia: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.1          Australia: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.2          Australia: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.5.3          Australia: Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

9.1.2.6          Rest of Asia Pacific: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.1          Rest of Asia Pacific: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.2          Rest of Asia Pacific: Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

9.1.2.6.3          Rest of Asia Pacific: Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)

10.        Impact Of COVID-19 Pandemic on Asia Pacific Diltiazem Market

10.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic

11.        Diltiazem Market–Industry Landscape

11.1      Overview

11.2      Recent Growth Strategies In The Diltiazem Market

12.        Company Profiles

12.1      Bausch Health Companies Inc.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Teva Pharmaceutical Industries Ltd

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      MYLAN N.V.

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      Pfizer Inc.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      Sandoz (Novartis AG)

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Sun Pharmaceutical Industries Ltd

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Hikma Pharmaceuticals PLC

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8      Zydus Cadila

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9      Glenmark

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Prevalence of Atrial Fibrillation in APAC (by Country)

Table 2.             China Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 3.             China Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 4.             Japan Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 5.             Japan Diltiazem Market, by Application, – Revenue and Forecast to 2028 (USD Million)

Table 6.             India Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 7.             India Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 8.             South Korea Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 9.             South Korea Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 10.          Australia Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 11.          Australia Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 12.          Rest of Asia Pacific Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)

Table 13.          Rest of Asia Pacific Diltiazem Market, by Application – Revenue and Forecast to 2028 (USD Million)

Table 14.          Glossary of Terms, Diltiazem Market

 

LIST OF FIGURES

Figure 1.           Diltiazem Market Segmentation

Figure 2.           Diltiazem Market Segmentation, By Country

Figure 3.           Diltiazem Market Overview

Figure 4.           Tablets Held the Largest Share of the Product Segment in Diltiazem Market

Figure 5.           Asia Pacific Diltiazem Market – Leading Country Markets (US$ Million)

Figure 6.           Asia Pacific PEST Analysis

Figure 7.           Diltiazem Market: Impact Analysis of Drivers and Restraints

Figure 8.           Asia Pacific Diltiazem Market – Revenue Forecast and Analysis – 2020- 2028

Figure 9.           Diltiazem Market Share by Product Type 2021 & 2028 (%)

Figure 10.        Capsules Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 11.        Injection Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 12.        Tablet Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 13.        Diltiazem Market Share by Application 2021 & 2028 (%)

Figure 14.        Angina Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 15.        Hypertension Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 16.        Others Market Revenue and Forecasts to 2028 (US$ Mn)

Figure 17.        Asia Pacific: Diltiazem Market, by Key Country – Revenue (2021) (USD Million)

Figure 18.        Asia Pacific: Diltiazem Market, by Country, 2021 & 2028 (%)

Figure 19.        China Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 20.        Japan: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 21.        India: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 22.        South Korea: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 23.        Australia: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 24.        Rest of Asia Pacific: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)

Figure 25.        Impact of COVID-19 Pandemic in Asia Pacific Country Markets

  1. Bausch Health Companies Inc.
  2. Teva Pharmaceutical Industries Ltd
  3. MYLAN N.V.
  4. Pfizer Inc.
  5. Sandoz (Novartis AG)
  6. Sun Pharmaceutical Industries Ltd
  7. Hikma Pharmaceuticals PLC
  8. Zydus Cadila
  9. Glenmark

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific diltiazem market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific diltiazem market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

 

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000